Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

Impact of Phosphodiesterase 4 Inhibition on the Operational Efficacy, Response Maxima, and Kinetics of Indacaterol-Induced Gene Expression Changes in BEAS-2B Airway Epithelial Cells: A Global Transcriptomic Analysis.

Joshi R, Yan D, Hamed O, Mostafa MM, Joshi T, Newton R, Giembycz MA.

Mol Pharmacol. 2019 Jul;96(1):56-72. doi: 10.1124/mol.118.115311. Epub 2019 Apr 29.

PMID:
31036559
2.

A bronchoprotective role for Rgs2 in a murine model of lipopolysaccharide-induced airways inflammation.

George T, Chakraborty M, Giembycz MA, Newton R.

Allergy Asthma Clin Immunol. 2018 Oct 1;14:40. doi: 10.1186/s13223-018-0266-5. eCollection 2018.

3.

Long-Acting β2-Adrenoceptor Agonists Enhance Glucocorticoid Receptor (GR)-Mediated Transcription by Gene-Specific Mechanisms Rather Than Generic Effects via GR.

Rider CF, Altonsy MO, Mostafa MM, Shah SV, Sasse S, Manson ML, Yan D, Kärrman-Mårdh C, Miller-Larsson A, Gerber AN, Giembycz MA, Newton R.

Mol Pharmacol. 2018 Sep;94(3):1031-1046. doi: 10.1124/mol.118.112755. Epub 2018 Jun 29.

PMID:
29959223
4.

Analysis of the Indacaterol-Regulated Transcriptome in Human Airway Epithelial Cells Implicates Gene Expression Changes in the Adverse and Therapeutic Effects of β2-Adrenoceptor Agonists.

Yan D, Hamed O, Joshi T, Mostafa MM, Jamieson KC, Joshi R, Newton R, Giembycz MA.

J Pharmacol Exp Ther. 2018 Jul;366(1):220-236. doi: 10.1124/jpet.118.249292. Epub 2018 Apr 13.

PMID:
29653961
5.

Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers.

Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz MA, Hoyer D, Insel PA, Izzo AA, Ji Y, MacEwan DJ, Sobey CG, Stanford SC, Teixeira MM, Wonnacott S, Ahluwalia A.

Br J Pharmacol. 2018 Apr;175(7):987-993. doi: 10.1111/bph.14153.

6.

Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology.

Alexander SPH, Roberts RE, Broughton BRS, Sobey CG, George CH, Stanford SC, Cirino G, Docherty JR, Giembycz MA, Hoyer D, Insel PA, Izzo AA, Ji Y, MacEwan DJ, Mangum J, Wonnacott S, Ahluwalia A.

Br J Pharmacol. 2018 Feb;175(3):407-411. doi: 10.1111/bph.14112. No abstract available.

7.

Inhibition of ABCC4 potentiates combination beta agonist and glucocorticoid responses in human airway epithelial cells.

Huff RD, Rider CF, Yan D, Newton R, Giembycz MA, Carlsten C, Hirota JA.

J Allergy Clin Immunol. 2018 Mar;141(3):1127-1130.e5. doi: 10.1016/j.jaci.2017.10.011. Epub 2017 Dec 6. No abstract available.

PMID:
29103996
8.

Updating the guidelines for data transparency in the British Journal of Pharmacology - data sharing and the use of scatter plots instead of bar charts.

George CH, Stanford SC, Alexander S, Cirino G, Docherty JR, Giembycz MA, Hoyer D, Insel PA, Izzo AA, Ji Y, MacEwan DJ, Sobey CG, Wonnacott S, Ahluwalia A.

Br J Pharmacol. 2017 Sep;174(17):2801-2804. doi: 10.1111/bph.13925. No abstract available.

9.

Protective Roles for RGS2 in a Mouse Model of House Dust Mite-Induced Airway Inflammation.

George T, Bell M, Chakraborty M, Siderovski DP, Giembycz MA, Newton R.

PLoS One. 2017 Jan 20;12(1):e0170269. doi: 10.1371/journal.pone.0170269. eCollection 2017.

10.

GS-5759, a Bifunctional β2-Adrenoceptor Agonist and Phosphodiesterase 4 Inhibitor for Chronic Obstructive Pulmonary Disease with a Unique Mode of Action: Effects on Gene Expression in Human Airway Epithelial Cells.

Joshi T, Yan D, Hamed O, Tannheimer SL, Phillips GB, Wright CD, Kim M, Salmon M, Newton R, Giembycz MA.

J Pharmacol Exp Ther. 2017 Feb;360(2):324-340. doi: 10.1124/jpet.116.237743. Epub 2016 Dec 7.

PMID:
27927912
11.

Understanding how long-acting β2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update.

Newton R, Giembycz MA.

Br J Pharmacol. 2016 Dec;173(24):3405-3430. doi: 10.1111/bph.13628. Epub 2016 Nov 9. Review.

12.
13.

Experimental design and analysis and their reporting: new guidance for publication in BJP.

Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA, Gilchrist A, Hoyer D, Insel PA, Izzo AA, Lawrence AJ, MacEwan DJ, Moon LD, Wonnacott S, Weston AH, McGrath JC.

Br J Pharmacol. 2015 Jul;172(14):3461-71. doi: 10.1111/bph.12856. No abstract available. Erratum in: Br J Pharmacol. 2015 Sep;172(18):4600.

14.

Potential mechanisms to explain how LABAs and PDE4 inhibitors enhance the clinical efficacy of glucocorticoids in inflammatory lung diseases.

Giembycz MA, Newton R.

F1000Prime Rep. 2015 Feb 3;7:16. doi: 10.12703/P7-16. eCollection 2015. Review.

15.

Cytokine-induced loss of glucocorticoid function: effect of kinase inhibitors, long-acting β(2)-adrenoceptor [corrected] agonist and glucocorticoid receptor ligands.

Rider CF, Shah S, Miller-Larsson A, Giembycz MA, Newton R.

PLoS One. 2015 Jan 27;10(1):e0116773. doi: 10.1371/journal.pone.0116773. eCollection 2015. Erratum in: PLoS One. 2015;10(5):e0128728.

16.
17.

Superiority of combined phosphodiesterase PDE3/PDE4 inhibition over PDE4 inhibition alone on glucocorticoid- and long-acting β2-adrenoceptor agonist-induced gene expression in human airway epithelial cells.

BinMahfouz H, Borthakur B, Yan D, George T, Giembycz MA, Newton R.

Mol Pharmacol. 2015 Jan;87(1):64-76. doi: 10.1124/mol.114.093393. Epub 2014 Oct 16.

PMID:
25324049
18.

Cyclic nucleotide-based therapeutics for chronic obstructive pulmonary disease.

Giembycz MA, Maurice DH.

Curr Opin Pharmacol. 2014 Jun;16:89-107. doi: 10.1016/j.coph.2014.04.001. Epub 2014 May 6. Review.

PMID:
24810285
19.

Tumour necrosis factor-α regulates human eosinophil apoptosis via ligation of TNF-receptor 1 and balance between NF-κB and AP-1.

Kankaanranta H, Ilmarinen P, Zhang X, Adcock IM, Lahti A, Barnes PJ, Giembycz MA, Lindsay MA, Moilanen E.

PLoS One. 2014 Feb 28;9(2):e90298. doi: 10.1371/journal.pone.0090298. eCollection 2014.

20.

How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype.

Giembycz MA, Newton R.

Clin Chest Med. 2014 Mar;35(1):203-17. doi: 10.1016/j.ccm.2013.09.007. Epub 2013 Dec 12. Review.

PMID:
24507847
21.

Induction of regulator of G-protein signaling 2 expression by long-acting β2-adrenoceptor agonists and glucocorticoids in human airway epithelial cells.

Holden NS, George T, Rider CF, Chandrasekhar A, Shah S, Kaur M, Johnson M, Siderovski DP, Leigh R, Giembycz MA, Newton R.

J Pharmacol Exp Ther. 2014 Jan;348(1):12-24. doi: 10.1124/jpet.113.204586. Epub 2013 Oct 25.

PMID:
24163441
22.

Concurrent agonism of adenosine A2B and glucocorticoid receptors in human airway epithelial cells cooperatively induces genes with anti-inflammatory potential: a novel approach to treat chronic obstructive pulmonary disease.

Greer S, Page CW, Joshi T, Yan D, Newton R, Giembycz MA.

J Pharmacol Exp Ther. 2013 Sep;346(3):473-85. doi: 10.1124/jpet.113.206284. Epub 2013 Jul 2.

PMID:
23820127
23.

Modulation of transcriptional responses by poly(I:C) and human rhinovirus: effect of long-acting β₂-adrenoceptor agonists.

Rider CF, Miller-Larsson A, Proud D, Giembycz MA, Newton R.

Eur J Pharmacol. 2013 May 15;708(1-3):60-7. doi: 10.1016/j.ejphar.2013.02.056. Epub 2013 Mar 20.

PMID:
23523474
24.
25.

Glucocorticoid repression of inflammatory gene expression shows differential responsiveness by transactivation- and transrepression-dependent mechanisms.

King EM, Chivers JE, Rider CF, Minnich A, Giembycz MA, Newton R.

PLoS One. 2013;8(1):e53936. doi: 10.1371/journal.pone.0053936. Epub 2013 Jan 14.

26.

Selectivity profiling of the novel EP2 receptor antagonist, PF-04418948, in functional bioassay systems: atypical affinity at the guinea pig EP2 receptor.

Birrell MA, Maher SA, Buckley J, Dale N, Bonvini S, Raemdonck K, Pullen N, Giembycz MA, Belvisi MG.

Br J Pharmacol. 2013 Jan;168(1):129-38. doi: 10.1111/j.1476-5381.2012.02088.x.

27.

Prostaglandin E2 represses interleukin 1 beta-induced inflammatory mediator output from pregnant human myometrial cells through the EP2 and EP4 receptors.

Mosher AA, Rainey KJ, Giembycz MA, Wood S, Slater DM.

Biol Reprod. 2012 Jul 5;87(1):7, 1-10. doi: 10.1095/biolreprod.112.100099. Print 2012 Jul.

PMID:
22517618
28.

β2-Adrenoceptor agonist-induced RGS2 expression is a genomic mechanism of bronchoprotection that is enhanced by glucocorticoids.

Holden NS, Bell MJ, Rider CF, King EM, Gaunt DD, Leigh R, Johnson M, Siderovski DP, Heximer SP, Giembycz MA, Newton R.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19713-8. doi: 10.1073/pnas.1110226108. Epub 2011 Nov 11.

29.
30.

Inflammatory stimuli inhibit glucocorticoid-dependent transactivation in human pulmonary epithelial cells: rescue by long-acting beta2-adrenoceptor agonists.

Rider CF, King EM, Holden NS, Giembycz MA, Newton R.

J Pharmacol Exp Ther. 2011 Sep;338(3):860-9. doi: 10.1124/jpet.111.181016. Epub 2011 May 27.

PMID:
21622733
31.

Salbutamol delays human eosinophil apoptosis via a cAMP-dependent mechanism.

Kankaanranta H, Parkkonen J, Ilmarinen-Salo P, Giembycz MA, Moilanen E.

Pulm Pharmacol Ther. 2011 Aug;24(4):394-400. doi: 10.1016/j.pupt.2011.03.002. Epub 2011 Mar 15.

PMID:
21396479
32.

Evidence for a second receptor for prostacyclin on human airway epithelial cells that mediates inhibition of CXCL9 and CXCL10 release.

Wilson SM, Sheddan NA, Newton R, Giembycz MA.

Mol Pharmacol. 2011 Mar;79(3):586-95. doi: 10.1124/mol.110.069674. Epub 2010 Dec 20.

PMID:
21173040
33.

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.

Giembycz MA, Field SK.

Drug Des Devel Ther. 2010 Jul 21;4:147-58. Review.

34.

Enhancement of inflammatory mediator release by beta(2)-adrenoceptor agonists in airway epithelial cells is reversed by glucocorticoid action.

Holden NS, Rider CF, Bell MJ, Velayudhan J, King EM, Kaur M, Salmon M, Giembycz MA, Newton R.

Br J Pharmacol. 2010 May;160(2):410-20. doi: 10.1111/j.1476-5381.2010.00708.x.

35.

Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.

Gross NJ, Giembycz MA, Rennard SI.

COPD. 2010 Apr;7(2):141-53. doi: 10.3109/15412551003758304. Review.

PMID:
20397815
36.

Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases.

Newton R, Leigh R, Giembycz MA.

Pharmacol Ther. 2010 Feb;125(2):286-327. doi: 10.1016/j.pharmthera.2009.11.003. Epub 2009 Nov 22. Review.

PMID:
19932713
37.

Selective prostacyclin receptor agonism augments glucocorticoid-induced gene expression in human bronchial epithelial cells.

Wilson SM, Shen P, Rider CF, Traves SL, Proud D, Newton R, Giembycz MA.

J Immunol. 2009 Nov 15;183(10):6788-99. doi: 10.4049/jimmunol.0902738. Epub 2009 Oct 30.

38.

Beta(2)-agonists block tussive responses in guinea pigs via an atypical cAMP-dependent pathway.

Freund-Michel VC, Birrell MA, Giembycz MA, Hele DJ, Haj-Yahia S, Belvisi MG.

Eur Respir J. 2010 Mar;35(3):647-54. doi: 10.1183/09031936.00034009. Epub 2009 Aug 13.

39.

Prostanoid receptor antagonists: development strategies and therapeutic applications.

Jones RL, Giembycz MA, Woodward DF.

Br J Pharmacol. 2009 Sep;158(1):104-45. doi: 10.1111/j.1476-5381.2009.00317.x. Epub 2009 Jul 15. Review.

40.

Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children.

Cowie RL, Giembycz MA, Leigh R.

Expert Opin Pharmacother. 2009 Aug;10(12):2009-14. doi: 10.1517/14656560903078428. Review.

PMID:
19618993
41.

An estimation of beta 2-adrenoceptor reserve on human bronchial smooth muscle for some sympathomimetic bronchodilators.

Giembycz MA.

Br J Pharmacol. 2009 Sep;158(1):287-99. doi: 10.1111/j.1476-5381.2009.00277.x. Epub 2009 May 14.

42.

Prostaglandin E(2) couples through EP(4) prostanoid receptors to induce IL-8 production in human colonic epithelial cell lines.

Dey I, Giembycz MA, Chadee K.

Br J Pharmacol. 2009 Feb;156(3):475-85. doi: 10.1111/j.1476-5381.2008.00056.x. Epub 2009 Jan 23.

43.

Nitric oxide inhibits human rhinovirus-induced transcriptional activation of CXCL10 in airway epithelial cells.

Koetzler R, Zaheer RS, Wiehler S, Holden NS, Giembycz MA, Proud D.

J Allergy Clin Immunol. 2009 Jan;123(1):201-208.e9. doi: 10.1016/j.jaci.2008.09.041. Epub 2008 Nov 4.

PMID:
18986693
44.

Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?

Giembycz MA.

Br J Pharmacol. 2008 Oct;155(3):288-90. doi: 10.1038/bjp.2008.297. Epub 2008 Jul 28.

45.

Effect of beta2-adrenoceptor agonists and other cAMP-elevating agents on inflammatory gene expression in human ASM cells: a role for protein kinase A.

Kaur M, Holden NS, Wilson SM, Sukkar MB, Chung KF, Barnes PJ, Newton R, Giembycz MA.

Am J Physiol Lung Cell Mol Physiol. 2008 Sep;295(3):L505-14. doi: 10.1152/ajplung.00046.2008. Epub 2008 Jun 27.

46.

Phosphodiesterase 4 inhibitors delay human eosinophil and neutrophil apoptosis in the absence and presence of salbutamol.

Parkkonen J, Hasala H, Moilanen E, Giembycz MA, Kankaanranta H.

Pulm Pharmacol Ther. 2008;21(3):499-506. doi: 10.1016/j.pupt.2007.11.003. Epub 2007 Nov 22.

PMID:
18282775
47.
49.
50.

Potentiation of NF-kappaB-dependent transcription and inflammatory mediator release by histamine in human airway epithelial cells.

Holden NS, Gong W, King EM, Kaur M, Giembycz MA, Newton R.

Br J Pharmacol. 2007 Nov;152(6):891-902. Epub 2007 Sep 24.

Supplemental Content

Loading ...
Support Center